UK Department for International Trade
A number of companies shown here with profiles and logos are financially supported by the UK government's Tradeshow Access Programme.
Cypralis was spun out from Selcia Ltd (Ongar, Essex) in 2013 to exploit its extensive expertise and know-how in targeting peptidyl-prolyl isomerases (known as PPIases), a large family of druggable protein targets involved in many acute and chronic diseases. Cypralis is dedicated to the discovery and development of innovative therapeutics for the inhibition of PPIases and expects to build upon its existing intellectual property estate through its own R&D activities and also through risk-sharing collaborations with pharmaceutical companies.
Mr Simon KerrChief Executive Officer
Dr Michael PeelChief Scientific Officer
Image Analysis Group
IA-Group is a strategic partner to bio-pharmacutical companies. We bring extensive therapeutic knowledge and regulatory expertise in strategic use of clinical imaging to enhance understanding of the mode of action, to increase the efficiency of clinical decisions and to accelerate drug development. IA‘s operations team leverage our global footprint and the next-generation cloud based proprietry platform Dynamika to de-risk trial execution and to ensure data quality and integrity. Our venture arm pioneer unique targeted investment and risk-sharing models to enable our clients to reach the next value inflection point faster. We fuse decades of theraputic insight and agile culture to meet today's speed and high standard of therapeutic innovation.
Dr Diana RoettgerHead of Scientific and Medical Affairs
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients.
Prof Clive MorrisChief Executive Officer
Dr Thomas SchlumpbergerVP Business Development
At Invisio we are creating innovative medicines helping to transform peoples’ lives, developing partnerships, working alongside organisations to ensure best care solutions are available as broadly as possible. Modern medicine involves tailoring the right therapy for the patient to ensure best results. We offer customers Pharmacogenetic Testing, an Adherence Monitoring App, and two oral liquid versions of medications for motor and non-motor symptoms of Parkinson's Disease, Stroke, MS, ALS and TBI.
Dr Bill GarnerMedical Director
Mr Al HansenChief Operating Officer
Karma Oncology Ltd
Karma Oncology, Ltd is a unique company which specializes in preparing tailored clinical development plans, clinical trial design and execution (everything from preparing the protocol through site selection, regulatory/ethics submissions, monitoring, project management, reporting and final study report writing). Of note, Karma Oncology successfully designed and executed an adaptive clinical trial with an autologous cell therapy product in Europe & North America and has designed and executed several CAR-T trials.
Headquartered in Scotland, the team of experts is based across Europe & North America, and experience encompasses solid tumours and haematological malignancies in a wide range of therapeutic approaches.
MGB Biopharma Ltd
MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise. Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens.
Dr Miroslav RavicCEO
Mr Raymond SpencerCFO
Pneumagen is developing novel therapeutics in infectious disease and oncology: neumific and neumonco.
Mr Douglas ThomsonDirector
Integrated drug discovery - hit identification, lead generation and lead optimisation using medicinal chemistry, computational chemistry and in vitro biology. Through long-term strategic alliances we incorporate X-ray crystallography, ADME/tox, in vivo PK, and in vivo disease models. Experience across a wide range of disease areas, such as respiratory, oncology and CNS, and biological targets, e.g. kinases, GPCRs, PPIs, NHRs & epigenetics. Clients located in the USA, Europe and Australasia.